

# A Dose-exploration Study of EDP167 in HoFH

NCT07489209

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Eddingpharm (Zhuhai) Co., Ltd.
<b>Enrollment</b>	20 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Age ≥18 years old, male or female, and weight ≥40 kg.
- Genetic diagnosis or clinical diagnosis of HoFH.
- Fasting serum LDL-C ≥2.6 mmol/L.
- Follow a daily low-fat diet during the study.
- Receiving stable and tolerable lipid-lowering treatment or other drugs for chronic diseases treatments for certain periods before the study, and maintain the stable treatments throughout the study.

... and 3 more (see full listing online)

### Exclusion (19)

- Allergic to the drug in this study, its components or similar drugs.
- Used any antisense oligonucleotide (ASO) or small interfering nucleic acid (siRNA) drugs within 12 months prior to randomization.
- Received treatment targeting ANGPTL3 or Apolipoprotein C3 (ApoC3), or have participated in other clinical trials within 6 months or 5 half-life (whichever longer) prior to screening.
- Received health supplements or other medications that have been used for lipid-lowering purposes within 4 weeks prior to screening.
- Received Lipoprotein apheresis within 8 weeks prior to screening.

... and 14 more (see full listing online)

## Locations (1 total)

---

Fuwai Hospital, Beijing, China